Page last updated: 2024-12-06

tribuzone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tribuzone: antirheumatic, anti-inflammatory agent with analgesic properties; minor descriptor (75-85); on-line search PHENYLBUTAZONE/AA (75-85); Index Medicus search PYRAZOLES (75-80), PHENYLBUTAZONE/AA (81-85) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65605
CHEMBL ID2106482
CHEBI ID135536
SCHEMBL ID2109159
MeSH IDM0263039

Synonyms (30)

Synonym
4-(4,4-dimethyl-3-oxopentyl)-1,2-diphenyl-3,5-pyrazolidinedione
3,5-pyrazolidinedione, 4-(4,4-dimethyl-3-oxopentyl)-1,2-diphenyl-
einecs 236-191-4
tribuzon
trimetazon [czech]
trimetazone
tribuzona [inn-spanish]
tribuzone [inn]
trimetazon
benetazon
brn 0765347
trimethazon
tribuzonum [inn-latin]
trimethazone
tribuzone
CHEBI:135536
4-(4,4-dimethyl-3-oxopentyl)-1,2-diphenylpyrazolidine-3,5-dione
D08630
tribuzone (prop.inn)
benetazon (tn)
13221-27-7
unii-duu9gva746
tribuzonum
tribuzona
duu9gva746 ,
CHEMBL2106482
tribuzone [who-dd]
SCHEMBL2109159
DTXSID70157434
Q4462940
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]